The University of Manchester in the UK has partnered with US-based biotech AVROBIO on the clinical development of an investigational gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Under the terms of the partnership, the University will sponsor the investigator-led phase I/II trial for Hunter syndrome which is expected to begin in 2021. Source: Pharmatimes, 06/10/2020